<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02856347</url>
  </required_header>
  <id_info>
    <org_study_id>16VADS03</org_study_id>
    <nct_id>NCT02856347</nct_id>
  </id_info>
  <brief_title>Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin</brief_title>
  <acronym>CMTpostopFDOPA</acronym>
  <official_title>Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to study a radiating diagnosis agent used in post surgery when the
      biological assessment highlighted a residual disease.

      This is an inter-regional multicentric, prospective study evaluating the benefit of PET
      F-DOPA imaging in involved node detection compared to standard imaging assessment in patient
      with medullary thyroid cancer.

      The purpose of the study is to evaluate the impact and performance of a new PET / CT
      (computerized tomography ) tracer targeting dopamine receptor in patient with residual
      ganglionar biological disease after initial surgery of medullary thyroid cancer compared to
      standard imaging.

      Obtained data will be compared to the &quot;gold standard&quot; based on :

        -  nodes cytology when they could be punctured

        -  histology when a new surgery will be recommended

        -  surveillance when the 2 first cases will be not applicable (imaging monitoring,
           evolution of thyrocalcitonin)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Analysis will be performed by node.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative rate of TRUE positive nodes with PET F-DOPA compared to standard imaging assessment.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Analysis will be performed by patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative rate of FALSE positive nodes with PET F-DOPA compared to standard imaging assessment.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Analyses will be performed by patient and by node.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative rate of TRUE positive and FALSE metastasis with PET F-DOPA compared to standard imaging assessment.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Analyses will be performed by patient and by metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modification rate of patient's care after PET F-DOPA exam.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Comparison of the modification of care (orientation to a surgery or a surveillance) decided after standard imaging assessment following result of TEP-FDOPA exam.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The concordance between the PET F-DOPA results of each centre and centralized review.</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Concordance (centre / reviewer) of PET F-DOPA result interpretation will be evaluated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Medullary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>PET 18-FDOPA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>18F-DOPA will be administered with an activity of 1.5-4 MBq/kg (MegaBecquerel) in the IV (Intra venous) tubing to decrease the extravasation risk and tracer lymphatic migration. The injection site will be distant from pathologic area (forearm).
PET CT exam will start 10 min after tracer injection and will cover the whole body (10 to 30 min).
Other series of images will be done 50 min after tracer injection. Images will be interpreted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-DOPA</intervention_name>
    <description>Injection of 18F-DOPA and PET / CT-scan assessment</description>
    <arm_group_label>PET 18-FDOPA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; or = 18 years.

          2. Patient with medullary thyroid cancer (sporadic or hereditary form).

          3. Patient treated by total thyroidectomy with uni or bi-lateral lymph node dissection
             (in the central and/or lateral neck compartment).

          4. Patient with elevated thyrocalcitonin rate &gt; or = 150 pg/ml assessed within 6 weeks or
             more after surgery.

          5. Patient with standard imaging assessment performed during 3 months before PET
             18-FDOPA.

          6. Standard imaging assessment including at least a cervical ultra-sound, a
             cervico-thoracic CT-scan and/or a cervico-thoraco-abdomino-pelvic CT-scan and a liver
             MRI.

          7. Patient able to be followed at least 6 months after PET 18-FDOPA.

          8. If women are breastfeeding, nursing should be discontinued during 24 hours after PET
             18-FDOPA.

          9. Patient must provide written informed consent prior to any specific procedure or
             assessment.

         10. Patient must be affiliated to the French Social Security System.

        Exclusion Criteria:

          1. Pregnant patient.

          2. Post-operative radiotherapy initiated before PET 18-FDOPA.

          3. Patient with PET 18-FDG performed within 24 hours before PET 18-FDOPA.

          4. Participation in any other clinical trial for therapeutic use.

          5. Patient with PET / CT-scan exam contra-indication.

          6. Any serious and/or unstable pre-existing psychological, familial, geographic or social
             condition that could interfere with medical follow-up and compliance to study
             procedures.

          7. Patient protected by law.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Slimane Zerdoud, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Claudius Regaud</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Slimane Zerdoud, MD</last_name>
    <phone>0033 05 31 15 56 28</phone>
    <email>zerdoud.slimane@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Haut-Lévêque</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elif Hindie, MD</last_name>
      <phone>+33 05 57 65 64 08</phone>
      <email>Elif.hindie@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Elif Hindie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Monteil, MD</last_name>
      <email>jaques.monteil@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Monteil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Taïeb, MD</last_name>
      <phone>+33 04 91 38 44 06</phone>
      <email>David.taieb@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>David Taïeb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Claude Eberle, MD</last_name>
      <phone>+33 04 67 61 85 82</phone>
      <email>Marie-Claude.Eberle@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Claude Eberle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Slimane Zerdoud, MD</last_name>
      <phone>+33 5 31 15 52 70</phone>
      <email>zerdoud.slimane@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Slimane Zerdoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>August 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2016</study_first_posted>
  <last_update_submitted>August 4, 2017</last_update_submitted>
  <last_update_submitted_qc>August 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>PET F-DOPA</keyword>
  <keyword>18-FDOPA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dihydroxyphenylalanine</mesh_term>
    <mesh_term>Salmon calcitonin</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

